NATIONAL COMPREHENSIVE CANCER NETWORK

NCCN Guidelines® recommend fedratinib (INREBIC®) as an initial treatment option (Category 1) for patients with higher-risk (intermediate-2 or high-risk) MF who have platelet counts ≥50 × 10 9/L... *NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way... Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed May 23, 2023. To view the most recent and complete version of the guideline, go online to NCCN.

Also known as: National Comprehensive Cancer Network, Inc, NCCN